Vaxcyte, Inc.
PCVX
株式のランク
#2080
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
株価
$64.29
最終同期: 2026-10-19
時価総額
$9.86B
変化（1日）
1.05%
変化（1年）
49.86%
国
US
取引 Vaxcyte, Inc. (PCVX)
カテゴリー
Healthcare
Vaxcyte, Inc.（PCVX）の発行済株式数
June 2026 時点の発行済株式数 144.49M
Vaxcyte, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 144.49M です。December 2023 の終わりには、同社は 97.16M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Vaxcyte, Inc.（PCVX）の発行済株式数の履歴（2017 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 144.49M | 18.44% |
| 2024 | 122.00M | 25.57% |
| 2023 | 97.16M | 49.75% |
| 2022 | 64.88M | 24.95% |
| 2021 | 51.92M | 75.74% |
| 2020 | 29.55M | 678.52% |
| 2019 | 3.80M | 4.57% |
| 2018 | 3.63M | 1.80% |
| 2017 | 3.57M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 75.72% |
US
|
|
| 396.00M | 174.06% |
US
|
|
| 478.91M | 231.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.96% |
NL
|
